NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Liver Fibrosis in Zambian HIV-HBV Co-infected Patients

CompletedN/A

Sponsor: University of Alabama at Birmingham

Conditions: Human Immunodeficiency Virus, HBV, Fibrosis, Liver, Cirrhosis, Liver, Hepatocellular Carcinoma

Interventions: Anti-HIV Agents

Countries: Zambia

A cohort of adults with HIV-HBV co-infection will be created in Lusaka, Zambia, to describe the short and long-term (up to 10 years of follow-up) HBV and liver outcomes, including the effectiveness of current therapies, and to identify the risk factors for major endpoints of interest, including HCC and HBV functional cure. This cohort will also create a pool of potential participants for in-depth mechanistic studies and clinical trials of novel HBV cure drugs.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Age 18 years or older
* Living with HIV infection
* Living with active HBV infection, defined as any single positive HBsAg assay
* Naïve to antiretroviral therapy or currently participating in HIV/HBV co-infection in IeDEA-SA

Exclusion Criteria:

* Unable or unwilling to provide informed consent
* Planning to relocate out of Lusaka district

Locations (1)

Lusaka, Lusaka Province, Zambia